I migliori medici di Immunoterapia con Keytruda (Pembrolizumab) all'estero — Pagina 3

La Dott.ssa Mariam Abu Zeid è un'oncologa clinica presso gli ospedali oncologici internazionali Shefaa Al Orman. È certificata dalla Società Europea di Oncologia Medica (ESMO). La Dott.ssa Abu Zeid tratta tumori solidi e neoplasie ematologiche. Ha conseguito un dottorato (Ph.D.) in Oncologia Clinica e Medicina Nucleare presso l'Università Ain Shams.

• Somministra chemioterapia, immunoterapia e trattamenti mirati per vari tipi di cancro.
• Supervisiona studi clinici oncologici e gestisce le tossicità legate al trattamento.
• Coordina l'assistenza ai pazienti all'interno di team multidisciplinari per la stadiazione e la diagnosi complesse.
• Esercita in un centro accreditato ESMO che tratta circa 6.000 pazienti all'anno.

Il Dr. Alemdar è specializzato in immunoterapia con Keytruda presso il Medical Park Antalya Hospital Complex, portando una vasta esperienza in oncologia medica.

• Certificato in oncologia medica dal 2018
• Oltre _doctor_9570_ anni di esperienza in medicina interna e oncologia
• Ha lavorato presso l'Ospedale Universitario Akdeniz, un'istituzione medica di primo piano

Il Dr. Auala Hubert porta 36 anni di esperienza in oncologia e radioterapia presso l'Hadassah Medical Center, specializzandosi in immunoterapia.

• Dirige il Centro per i tumori gastrointestinali – profonda competenza in casi complessi
• Formato presso l'Hadassah University Hospital – uno dei principali centri oncologici in Israele
• Membro attivo di numerosi comitati di ricerca e trattamento del cancro

Il Professore Associato Muhammed Mustafa Atci è specializzato in oncologia medica presso l'İstinye University Liv Hospital Topkapı, con un forte focus sui trattamenti di immunoterapia.

• Membro dell'American Society of Clinical Oncology (ASCO)
• Ha pubblicato numerosi articoli sottoposti a revisione paritaria sui risultati del trattamento del cancro
• Coordinatore della formazione per la sottosezione di oncologia medica
• Vasta esperienza nel trattamento di vari tipi di cancro con l'immunoterapia

Il Dr. Ozden porta oltre _doctor_10151_anni_ di esperienza in oncologia medica nel suo ruolo presso l'ospedale VM Medical Park Pendik.

• Specializzato in Oncologia Medica presso l'Università di Kocaeli
• Laureato al programma medico in lingua inglese dell'Università di Istanbul
• Ha lavorato in diversi ospedali specializzandosi in medicina interna

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

La Dott.ssa Maha Yahia è oncologa medica ed ematologa presso gli ospedali oncologici internazionali Shefaa Al Orman. Ha prestato servizio come medico con il grado di tenente colonnello nel Corpo Medico delle Forze Armate Egiziane. La Dott.ssa Yahia è specializzata nella pianificazione del trattamento per i tumori al seno, toracici e gastrointestinali. Si concentra sull'immunoterapia, sulla terapia mirata e su protocolli chemioterapici complessi.

• Ex responsabile del team di supporto alla ricerca clinica presso il Maadi AFMC.
• Formata presso l'Istituto Nazionale dei Tumori dell'Università del Cairo in emato-oncologia.
• Tratta tumori genito-urinari, ginecologici e rari, oltre a patologie ematologiche.
• Lavora in un centro accreditato ESMO che tratta 6.000 pazienti all'anno.

Il Dr. Emad Shash è un oncologo medico che ha partecipato a oltre 70 studi clinici oncologici. Ricopre il ruolo di Direttore Medico dell'Ospedale Oncologico Integrato per il Seno presso il NCI. Il Dr. Shash è specializzato in terapie sistemiche, tra cui chemioterapia, terapia mirata e immunoterapia. Possiede un diploma JCI in Gestione della Qualità Ospedaliera e Sicurezza del Paziente.

• Membro votante del panel ESMO e membro del comitato ASCO.
• Tratta tumori al seno, ginecologici, genito-urinari, toracici, gastrointestinali e tumori rari.
• Ex medico ricercatore e responsabile medico presso l'EORTC di Bruxelles.
• Lavora presso Shefaa Al Orman, un centro oncologico accreditato ESMO che tratta 6.000 pazienti all'anno.

Il Dr. Raanan Berger è il direttore del Centro Oncologico dello Sheba Medical Center. È stato inserito nella lista dei "Migliori Medici" di Forbes Israele nel 2025. Il Dr. Berger è specializzato in oncologia genitourinaria e tratta tumori complessi alla prostata con radioterapia. Ha completato un post-dottorato presso il Dana-Farber/Harvard Cancer Institute.

• Dirige l'unità di ricerca clinica focalizzata sull'oncologia molecolare.
• Coautore di oltre 20 articoli sottoposti a revisione paritaria sul cancro alla prostata e sulle mutazioni BRCA.
• Membro dell'American Society of Clinical Oncology (ASCO).
• Esegue terapie sistemiche e radioterapia in un ospedale classificato tra i primi 10 al mondo.

Il Dr. Jair Bar è un oncologo toracico e vicedirettore del Centro Oncologico presso lo Sheba Medical Center. È specializzato nel trattamento del tumore al polmone non a piccole cellule in stadio avanzato mediante immunoterapia personalizzata e terapie mirate. Il Dr. Bar ha conseguito un dottorato di ricerca in Biologia Molecolare e dirige un laboratorio di ricerca focalizzato sulla resistenza all'immunoterapia.

• Presidente dell'Israel Lung Cancer Group.
• Certificato in Oncologia Medica e Radioterapia Oncologica.
• Tratta i pazienti presso lo Sheba Medical Center, uno dei 10 migliori ospedali al mondo.
• Utilizza la profilazione molecolare e genetica per creare piani di trattamento oncologico precisi.

Il Dr. Eytan Aharon Ben-Ami dirige la Divisione di Oncologia presso il Sheba Medical Center in Israele. Si è specializzato in sarcomi e oncologia ossea presso il Dana-Farber Cancer Institute. Il Dr. Ben-Ami ha fondato la Sheba Clinical Research Organization per far progredire gli studi sul cancro. Tratta tumori ossei rari e sarcomi dei tessuti molli con protocolli personalizzati.

• Dirige l'unità di sperimentazione clinica di fase precoce per terapie oncologiche innovative.
• Autore di oltre 40 pubblicazioni scientifiche sui meccanismi molecolari e la diagnosi precoce.
• Guida studi di Fase I in terapia mirata e immunoterapia per tumori rari.
• Lavora presso il Sheba Medical Center, uno dei 10 migliori ospedali al mondo secondo Newsweek.

Primario del Centro di Oncologia presso l'Assuta Medical Center, specializzato in trattamenti di immunoterapia.

• Oncologo con vasta esperienza in terapie mirate
• Guida un team dedicato a trattamenti oncologici avanzati
• Si concentra su piani di trattamento personalizzati per i pazienti

Vice primario del Dipartimento di Oncologia presso il Rambam Medical Center – Il Dr. Bar-Sela è specializzato in trattamenti oncologici all'avanguardia.

• Esperto in immunoterapia con Keytruda (pembrolizumab)
• Specializzato in piani di trattamento oncologico personalizzati
• Lavora presso un dipartimento di oncologia leader in Israele

Specialista israeliano di spicco nell'immunoterapia del cancro ai polmoni – il Prof. Peled dirige l'Unità di Oncologia Toracica presso il Davidoff Cancer Center.

• Esperto in Medicina Interna, Pneumologia e Oncologia Medica
• Vincitore del premio ASCO MERIT per la ricerca eccezionale
• Capo dell'Unità di Ricerca e Rilevamento delle neoplasie toraciche presso lo Sheba Medical Center
• Presidente del Comitato per la diagnosi precoce e la prevenzione dell'IASLC

Il Professor Bosch guida la ricerca globale sulla leucemia linfatica cronica (LLC) e sui trattamenti per i linfomi, con oltre 80 studi clinici attivi.

• Specializzato in linfomi e LLC presso l'Hospital Quiron di Barcellona
• Ha pubblicato oltre 100 articoli su riviste di alto livello come NEJM e Nature Medicine
• Direttore di Ematologia presso l'Ospedale Universitario Vall d'Hebron
• Sviluppa nuovi approcci terapeutici per i disturbi linfoproliferativi

Il Prof. Associato Nail Paksoy è specializzato in immunoterapia presso l'ospedale Medipol Bahçelievler, con una vasta esperienza in studi clinici che coinvolgono Keytruda.

• Certificato ESMO in Oncologia Medica
• Co-investigatore in molteplici studi internazionali di immunoterapia
• Ricerca pubblicata sui trattamenti oncologici avanzati
• Doppia specializzazione in Oncologia Medica e Allergologia-Immunologia

Il Prof. Baytan è specializzato in oncologia pediatrica ed ematologia, con una vasta esperienza nei trattamenti di leucemia e linfoma.

• Laureato presso la Facoltà di Medicina dell'Università di Ankara
• Ha pubblicato 15 articoli su riviste internazionali
• Specializzato nei trattamenti per la carenza di ferro e vitamine
• Lavora presso l'Ospedale Emsey

Il Dr. Weidmann dirige il settore di Ematologia presso la Clinica Nordwest con 36 anni di esperienza nel trattamento dei disturbi del sangue.

• Specializzato in casi di linfoma non-Hodgkin
• Professore con ampie credenziali accademiche
• Lavora presso la Clinica Nordwest, un centro ematologico di primo piano